News
Stalicla completes phase 1b trials into precision medicine for autism spectrum disorder
Swiss clinical stage biotech company, Stalicla, has announced the highly successful completion of phase 1b trials for its lead drug candidate, STP1.
You're using an outdated browser. To get the most out of this website, as well as many others, please consider upgrading to a modern browser, such as Google Chrome, Mozilla Firefox, or Microsoft Edge.
Swiss clinical stage biotech company, Stalicla, has announced the highly successful completion of phase 1b trials for its lead drug candidate, STP1.